FDA New Drug and Biologic Approvals, 2018 Midyear Review

Mary L Windle, PharmD

Disclosures

August 01, 2018

In This Article

Unresectable or Metastatic Melanoma: Mektovi (binimetinib)

Indication: Indicated in combination with encorafenib for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Mechanism: Inhibits mitogen-activated extracellular signal regulated kinase (MEK) 1 and MEK 2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK)-related phosphorylation and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines.

Dosage: 45 mg PO BID in combination with encorafenib until disease progression or unacceptable toxicity. Dose modifications are recommended for toxicities.

Approval was based on results from the phase 3 COLUMBUS trial, which demonstrated that the combination doubled median progression-free survival (mPFS) compared with vemurafenib alone (14.9 months versus 7.3 months, respectively (P<0.0001).

Reference:

  • Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. https://www.ncbi.nlm.nih.gov/pubmed/29573941

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....